The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Abstract
PURPOSE: The nucleoside analog, gemcitabine, has shown activity as a single agent in the treatment of metastatic non-small-cell lung cancer (NSCLC). Its combination with cisplatin in preclinical models suggested synergy between the two drugs. The aim of the study was to evaluate the clinical efficacy and toxicity of the cisplatin-gemcitabine combination in advanced NSCLC. PATIENTS AND METHODS: Forty-eight consecutive previously untreated NSCLC patients entered the trial from January to June 1994. The median age was 60 years (range, 37 to 70) and performance status (PS) was 0 or 1; 22 patients had unresectable stage III disease (21 stage IIIB and one stage IIIA) and 26 had stage IV disease. Gemcitabine 1 g/m2 was administered weekly (days 1, 8, and 15) followed by a 1-week rest and cisplatin 100 mg/m2 on day 2 of each 28-day cycle. Survival and response were determined in accordance with the intention-to-treat principle in all enrolled patients. RESULTS: Of 48 assessable patients, one (stage IV) had a complete response (CR) and 25 achieved a partial response (PR). The overall response rate was 54% (95% confidence interval [CI], 40% to 68%). Thrombocytopenia was the main side effect, with 52% of patients experiencing grade III to IV toxicity, which was usually short-lived and responsible for the omission of gemcitabine administration on day 15 in 50% of chemotherapy courses. The median survival time was 61.5 weeks (95% CI, 40 to 71). CONCLUSION: The combination of gemcitabine and cisplatin induced a high response rate in both stage IIIB and IV NSCLC, with modest side effects. The regimen deserves further careful evaluation in a phase III prospective randomized trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1991) · PubMed · Cited by 876
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C., & Grindey, G. B. (1990) · PubMed · Cited by 680
Heinemann, V., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1988) · PubMed · Cited by 504
Wood, A. J. J., & Ihde, D. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272006 · Cited by 428
Anderson, H., Lund, B., Bach, F., Thatcher, N., Walling, J., & Hansen, H. H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1821 · Cited by 374
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., & Rugg, T. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1535 · Cited by 359
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
Ruckdeschel, J. C., Finkelstein, D. M., Ettinger, D. S., Creech, R. H., Mason, B. A., Joss, R., & Vogl, S. E. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.1.14 · Cited by 338
Synergistic interaction between cisplatin and gemcitabine in vitro.
Bergman, A. M., van Haperen, V. W. T. R., Veerman, G., Kuiper, C. M., & Peters, G. J. (1996) · PubMed · Cited by 304
Shewach, D. S., Hahn, T. M., Chang, E., Hertel, L. W., & Lawrence, T. S. (1994) · PubMed · Cited by 228
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
Fossella, F., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K. V., Ramlau, R., Szczęsna, A., Fidias, P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.046 · Cited by 939
Nucleoside analogues: mechanisms of drug resistance and reversal strategies
Galmarini, C., Mackey, Jr., & Dumontet, C. (2001) · Leukemia · doi:10.1038/sj.leu.2402114 · Cited by 511
Metadata
- Authors
- Crinò, L., Scagliotti, G., Marangolo, M., Figoli, F., Clerici, M., De Marinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Pucci, F., Paccagnella, A., Adamo, V, Altavilla, G., Incoronato, P., Trippetti, M., Mosconi, A. M., Santucci, A., Sorbolini, S., Oliva, C., & Tonato, M.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-01
- Volume
- 15
- Issue
- 1
- Pages
- 297-303
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1938837918
- Cited by
- 303
- References
- 12
- FWCI
- 31.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. https://app.cochat.ai/papers/10.1200/jco.1997.15.1.297
- The paper
- Crinò, L., Scagliotti, G., Marangolo, M., Figoli, F., Clerici, M., De Marinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Pucci, F., Paccagnella, A., Adamo, V, Altavilla, G., Incoronato, P., Trippetti, M., Mosconi, A. M., Santucci, A., Sorbolini, S., Oliva, C., & Tonato, M. (1997). Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1997.15.1.297
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.